Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Journal of Comparative Effectiveness Research
|
November 23, 2022
Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma
Sally D Miller, Greta Lozano-Ortega, Alex Mutebi, et al.
International Journal of Pharmaceutics
|
August 23, 2024
Effect of orientation angle for needle-free jet injection
Idera Lawal, Daniel de Castro Araujo Valente, Emil Khusnatdinov, et al.
Advances in Therapy
|
February 1, 2024
Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis
Andrew Ip, Alex Mutebi, Tongsheng Wang, et al.
Clinical Pharmacology and Therapeutics
|
August 23, 2022
Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas
Tommy Li, Ida H Hiemstra, Christopher Chiu, et al.
Journal of Hematology & Oncology
|
August 16, 2024
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
Allison Rosenthal, Javier Munoz, Monika Jun, et al.
Clinical Pharmacology and Therapeutics
|
July 7, 2026
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation
Tommy Li, Andrew Tredennick, Daniel Polhamus, et al.
Lancet (London, England)
|
September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Martin Hutchings, Rogier Mous, Michael Roost Clausen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2022
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
Catherine Thieblemont, Tycel Phillips, Herve Ghesquieres, et al.
The Lancet. Haematology
|
June 18, 2024
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
Kim M Linton, Umberto Vitolo, Wojciech Jurczak, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Journal of Comparative Effectiveness Research
|
November 23, 2022
Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma
Sally D Miller, Greta Lozano-Ortega, Alex Mutebi, et al.
International Journal of Pharmaceutics
|
August 23, 2024
Effect of orientation angle for needle-free jet injection
Idera Lawal, Daniel de Castro Araujo Valente, Emil Khusnatdinov, et al.
Advances in Therapy
|
February 1, 2024
Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis
Andrew Ip, Alex Mutebi, Tongsheng Wang, et al.
Clinical Pharmacology and Therapeutics
|
August 23, 2022
Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas
Tommy Li, Ida H Hiemstra, Christopher Chiu, et al.
Journal of Hematology & Oncology
|
August 16, 2024
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
Allison Rosenthal, Javier Munoz, Monika Jun, et al.
Clinical Pharmacology and Therapeutics
|
July 7, 2026
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation
Tommy Li, Andrew Tredennick, Daniel Polhamus, et al.
Lancet (London, England)
|
September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Martin Hutchings, Rogier Mous, Michael Roost Clausen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2022
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
Catherine Thieblemont, Tycel Phillips, Herve Ghesquieres, et al.
The Lancet. Haematology
|
June 18, 2024
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
Kim M Linton, Umberto Vitolo, Wojciech Jurczak, et al.
Page
of 2